Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Final Survival Data From a Randomized Phase 2 Trial Comparing High-Dose With Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited Stage SCLC"
Login to view comments.
Click here to Login